Apollo Hospitals Enterprise - Comprehensive Analysis 2026
- Analysis Date: June 25, 2026
- Exchange: NSE (Primary) / BSE
- Sector: Healthcare — Integrated Hospitals, Pharmacy & Digital Health
- Market Cap: Rs. 1,23,520 Cr (Large Cap — Nifty 50 constituent)
Executive Summary
Fundamental Score: 6.7/10 ⭐⭐⭐
Investment Recommendation: Buy on Dips (Medium-High Conviction)
Conviction Level: Medium-High
Target Price: Rs. 10,000-10,500 (~16-22% upside) — 12-18 month horizon
Key Thesis: Apollo Hospitals is India's premium integrated healthcare platform combining the country's largest private hospital network (10,200 beds, 73 facilities), Apollo Pharmacy (6,000+ stores), and Apollo 24|7 digital health. The company has demonstrated consistent 15% revenue CAGR (FY22-FY26) and accelerating profitability (net profit CAGR 15.9%) with first-time positive FCF of Rs. 925 Cr in FY26. At PE 63.2x, it trades at a discount to Max Healthcare (74.2x) despite superior ROE (22.1% vs 14.8%), making it the most quality-adjusted value among large-cap Indian hospital stocks. Near-term catalyst: Apollo Healthtech demerger (NCLT meeting June 24, 2026) could significantly unlock value.
Business Overview
Company Profile:
Apollo Hospitals Enterprise Limited was founded in 1983 by Dr. Prathap C. Reddy in Chennai, widely credited as the pioneer of private healthcare in India. The company operates through three integrated verticals: Healthcare Services (hospitals), Apollo Pharmacy (retail pharmacy chain), and Apollo HealthCo (digital health platform — Apollo 24|7).
Business Model:
- Healthcare Services (Hospitals): ~55-60% of consolidated revenue — 10,200 operational beds across 73 facilities (45 owned hospitals + 6 management contracts). Revenue driven by in-patient admissions (ARPOB — Average Revenue Per Occupied Bed), day-care procedures, and international medical tourism.
- Apollo Pharmacy: ~35-40% of consolidated revenue — India's largest pharmacy chain with 6,000+ stores. Lower margin (~3-5% OPM) but high-volume, asset-light growth with significant scale moat.
- Apollo HealthCo / Apollo 24|7: Digital health subsidiary with telehealth consultations, e-pharmacy, diagnostics booking, and health records. High-growth, pre-profit segment building the digital health ecosystem.
Why OPM Looks Lower Than Peers: Apollo's consolidated OPM (15%) appears lower than Fortis (23%) and Max Healthcare (27%) because Apollo consolidates high-revenue, low-margin pharmacy operations. The hospital-only EBITDA margin is estimated at 20-22%, comparable to sector peers. This is critical for valuation comparison.
Market Position:
- #1 Private Hospital Network in India by beds (10,200 beds)
- #1 Pharmacy Chain in India (Apollo Pharmacy, 6,000+ stores)
- #1 in Medical Tourism: Premier destination for international patients (Middle East, Africa, Southeast Asia)
- Nifty 50 constituent: One of the two large-cap healthcare stocks in India's benchmark index
Key Competitors:
| Segment | Competitors |
|---|---|
| Hospitals (Pan-India) | Max Healthcare, Fortis Healthcare |
| Hospitals (South India) | Narayana Hrudayalaya, Manipal Hospitals (unlisted) |
| Pharmacy Retail | MedPlus Health (listed), Netmeds (Reliance), PharmEasy (unlisted) |
| Digital Health | Practo, 1mg (Tata), Bajaj Health |
Competitive Moat (Strong — 9/10):
- Brand: "Apollo" is the most trusted healthcare brand in India — 40+ years of trust, associated with complex tertiary care and medical breakthroughs
- Scale: 10,200 beds is 3-4x the capacity of closest listed peers — critical mass for attracting top doctors, complex cases, and international patients
- Apollo Pharmacy Integration: 6,000+ stores create captive pharmacy revenue for hospital discharge patients — powerful flywheel
- Medical Tourism: Apollo commands premium ARPOB from international patients (~3-5x domestic rates). Geographic diversification of revenue
- Digital Ecosystem (Apollo 24|7): Connecting patients to Apollo services across telehealth, pharmacy, diagnostics — early mover with first-party healthcare data moat
- Physician Attraction: Scale, brand, and technology attract India's best doctors — creating virtuous cycle
Management Quality:
- Leadership: Dr. Prathap C. Reddy (Executive Chairman, founder) with the Reddy family providing continuity. Suneeta Reddy (MD) and Sangita Reddy (JMD) lead operations and innovations respectively.
- Track Record: Pioneer of corporate healthcare in India; successfully built and maintained #1 position across 40+ years. Navigated COVID disruption effectively.
- Capital Allocation: Apollo HealthCo demerger demonstrates strategic clarity — separating growth/tech assets from stable hospital assets. Consistent bed expansion (targeting 2,000+ new beds over next 3 years).
- Concerns: Promoter holding at 28.02% is low for a family-run conglomerate — possible continued dilution from fundraising for expansion and HealthCo investments.
Corporate Governance:
- Promoter Holding: 28.02% (Low — below ideal 50%+ for Indian family promoter groups)
- Promoter Pledge: 2.49% (Low — acceptable, not a red flag at this level)
- FII Holding: 42.62% (Very High — strong international institutional confidence; global health investors including Vanguard, Government of Singapore, and LIC hold significant stakes)
- DII Holding: 22.76% (Healthy domestic institutional presence)
Financial Analysis
Revenue and Profit Trends
Annual Performance (Consolidated, FY22-FY26)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 | YoY FY26 |
|---|---|---|---|---|---|---|
| Revenue (Rs. Cr) | 14,663 | 16,612 | 19,059 | 21,794 | 25,228 | +16% |
| Operating Profit (Rs. Cr) | 2,189 | 2,065 | 2,394 | 3,033 | 3,769 | +24% |
| OPM (%) | 15% | 12% | 13% | 14% | 15% | +1 pp |
| Net Profit (Rs. Cr) | 1,108 | 844 | 935 | 1,505 | 2,003 | +33% |
| EPS (Rs.) | 73.42 | 56.97 | 62.50 | 100.56 | 135.04 | +34% |
Revenue CAGR Analysis:
- 4-Year CAGR (FY22-FY26): 14.5%
- 5-Year CAGR: ~15-19% (varies by standalone vs consolidated)
- 3-Year CAGR: 13%
Profit Trajectory:
- FY23 dip (Rs. 844 Cr) was due to COVID normalization and pharmacy investment ramp-up
- Strong recovery and acceleration: FY24 (935 Cr) → FY25 (1,505 Cr) → FY26 (2,003 Cr)
- Net Profit CAGR FY22-FY26: ~15.9%
- Net Profit CAGR FY24-FY26: ~46% (accelerating)
Operating Margin Analysis:
- OPM improved from 12% trough (FY23) back to 15% (FY26)
- Hospital segment EBITDA margin estimated 20-22% (standalone)
- Pharmacy segment OPM ~3-5% (dilutes consolidated OPM)
- Path to 16-18% consolidated OPM as pharmacy scales and hospital mix improves
Quarterly Performance (FY26)
| Quarter | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | QoQ Trend |
|---|---|---|---|---|---|
| Sales (Rs. Cr) | 5,592 | 5,842 | 6,304 | 6,477 | ⬆️ Consistent |
| OPM (%) | 13.8% | 14.6% | 14.9% | 14.9% | ⬆️ Improving |
| Net Profit (Rs. Cr) | 414 | 441 | 494 | 516 | ⬆️ Consistent |
Quarterly Trend:
- Q4 FY26 (Rs. 6,477 Cr, Rs. 516 Cr profit) is the best quarter ever
- Sequential improvement every quarter — demonstrates operational leverage
- Q4 annualized run rate: Rs. 25,908 Cr revenue, Rs. 2,064 Cr profit
Margin Analysis
| Margin | FY24 | FY25 | FY26 | Trend | Hospital-Only Est. | Max HC (Peer) |
|---|---|---|---|---|---|---|
| OPM (Consolidated) | 13% | 14% | 15% | ⬆️ | ~20-22% | 27% |
| Net Profit Margin | 4.9% | 6.9% | 7.9% | ⬆️ | ~12-14% | ~17% |
Critical Note: Apollo's lower consolidated OPM vs Max Healthcare directly reflects pharmacy business mix. Max Healthcare has no significant pharmacy operations. Apollo's hospital-only EBITDA margin (~20-22%) is broadly comparable to peers. The pharmacy business is a strategic moat, not a margin drag to be concerned about.
Cash Flow Quality
| Metric | FY26 (Rs. Cr) | Assessment |
|---|---|---|
| Operating Cash Flow | 2,856 | ✅ Strong — Rs. 11.3 per share annually |
| Investing Activity | -2,148 | Capex for bed expansion (growth investment) |
| Financing Activity | -478 | Debt repayment + dividends |
| Free Cash Flow (FCF) | 925 | ✅ First significant positive FCF — major milestone |
| Cash Conversion Cycle | -89 days | ✅ Exceptional — company collects before it pays |
Cash Flow Assessment:
- Positive FCF (Rs. 925 Cr) after years of heavy capex — signals transition to cash-generative phase
- Operating CF (Rs. 2,856 Cr) demonstrates strong underlying business economics
- -89 day cash conversion cycle is outstanding — hospitals collect at discharge (or via insurance), pharmacies collect immediately, but pay suppliers 144 days later. Working capital is a net source of cash.
- Capex trend: Rs. 2,148 Cr investing activity primarily for bed expansion. Apollo is targeting 2,000+ new beds over next 3 years. This will constrain FCF near-term but builds long-term capacity.
- Capex intensity will continue: FCF may remain modest (Rs. 500-1,000 Cr range) as expansion continues through FY28.
Cash Flow Rating: 7/10 — Improving and positive, constrained by legitimate growth capex.
Balance Sheet Strength
| Metric | Mar 2026 (Rs. Cr) | Analysis |
|---|---|---|
| Total Equity | 9,480-9,963 | Strong equity base |
| Borrowings (Debt) | 3,190-8,493 | Note: Higher figure includes lease liabilities and HealthCo debt |
| Debt-to-Equity | 0.32x | ✅ Manageable leverage |
| Total Assets | 22,197 | Predominantly fixed assets (hospitals) |
| Fixed Assets | 12,312 | Hospital infrastructure (tangible assets) |
| Interest Coverage | 9.6x | ✅ Very comfortable — minimal financial risk |
| Book Value per Share | Rs. 659-693 |
Note on Debt: The Rs. 8,493 Cr figure includes Ind AS 116 lease liabilities for hospital properties and Apollo HealthCo debt. The Rs. 3,190 Cr (standalone) reflects actual bank borrowings. D/E of 0.32x is on bank debt basis.
Balance Sheet Rating: 7/10 — Solid foundation with fixed asset backing. Debt is manageable and well-covered.
Shareholding Pattern (India-Specific)
| Category | Mar 2026 | Assessment |
|---|---|---|
| Promoter Holding | 28.02% | ⚠️ Low — well below ideal 50%+ for family-run business |
| Promoter Pledge | 2.49% | ✅ Low — not a red flag at this level |
| FII Holding | 42.62% | ✅✅ Very Strong — highest FII ownership among Indian hospital stocks |
| DII Holding | 22.76% | ✅ Healthy domestic institutional presence |
| Government | 0.23% | Small stake |
| Public | 6.39% | Low retail participation |
Key Observations:
-
Promoter Holding (28.02%) — The Main Concern:
- Well below ideal 50%+ for Indian promoter groups
- Reddy family has diluted over decades to fund hospital expansion and HealthCo investments
- Risk: Further equity raises could dilute promoter below 25% (creates governance concerns)
- Positive: Promoters maintain operational control despite low holding; no indication of promoter exit
-
FII Holding (42.62%) — World-Class Institutional Confidence:
- Highest FII ownership among major Indian hospital groups
- Global investors include Vanguard (US), Government of Singapore Investment Corporation, and LIC (India's largest insurer)
- Such concentration of sophisticated global capital signals high quality business
- Risk: Large FII position = FII exit risk if global risk-off; also limits further FII upside
-
Combined Institutional (65.38%):
- FII + DII = 65.38% — effectively institutionally owned
- Free float is high (71.98%) = good liquidity for large transactions
- High institutional ownership stabilizes the stock relative to retail-heavy peers
-
Pledge (2.49%) — Acceptable:
- Low pledge percentage; does not raise governance concerns
- Well below 10% threshold for concern
Shareholding Rating: 5/10 — High-quality institutional base but promoter ownership is below ideal. Risk of further dilution is real.
Valuation
Peer Comparison Matrix
| Metric | Apollo Hospitals | Max Healthcare | Fortis | Narayana H | Assessment |
|---|---|---|---|---|---|
| Current Price (Rs.) | 8,591 | 1,132 | 966 | 1,949 | — |
| Market Cap (Rs. Cr) | 1,23,520 | 1,10,171 | 72,929 | 39,825 | Largest by far |
| Revenue FY26 (Rs. Cr) | 25,228 | 8,373 | 9,128 | 7,896 | 3x peers |
| Net Profit FY26 (Rs. Cr) | 2,003 | 1,442 | 1,064 | 806 | Highest |
| OPM (%) | 15%* | 27% | 23% | 20% | *Pharmacy-diluted |
| PE Ratio | 63.2x | 74.2x | 68.9x | 46.8x | Cheapest ex-NH |
| Price/Book | 13.1x | 10.3x | 7.5x | 8.9x | Premium |
| EV/EBITDA | 46.8x | ~55x est. | ~45x est. | ~35x est. | Premium sector |
| ROE | 22.1% | 14.8% | 11.3% | 20.9% | Highest |
| ROCE | 17.9% | 14.7% | 13.5% | 15.4% | Highest |
| Debt/Equity | 0.32x | 0.36x | 0.35x | 1.29x | Conservative |
| Dividend Yield | 0.22% | Low | Low | Low | All low |
*Apollo OPM includes pharmacy retail (3-5% OPM); hospital segment OPM estimated 20-22%
Valuation Deep Dive
1. PE Ratio (63.2x) — Expensive in Absolute Terms, Cheapest Quality-Adjusted:
- Apollo PE (63.2x)
<Max Healthcare (74.2x)<Fortis (68.9x) - Apollo has HIGHER ROE (22.1%) and HIGHER ROCE (17.9%) than both Max and Fortis
- PEG-equivalent (PE/ROE): Apollo = 2.86 vs Max = 5.01 vs Fortis = 6.09
- Apollo is the CHEAPEST stock on quality-adjusted PE among large-cap hospital stocks
- Only Narayana (46.8x PE, 20.9% ROE, PEG = 2.24) is cheaper, but carries high D/E (1.29x)
2. Price/Book (13.1x) — Premium Justified by ROE:
- High PB reflects market pricing in intangible assets: brand value, 40-year reputation, physician network
- PB/ROE (Lower = Cheaper): Apollo = 0.593 vs Max = 0.696 vs Fortis = 0.664
- Apollo is cheaper than Max and Fortis on PB-adjusted-for-ROE basis
3. Forward Valuation (FY27E):
- FY27E EPS estimate: Rs. 165-175 (assuming ~23-30% net profit growth continuation)
- At 60x forward PE: Target Rs. 9,900-10,500
- At 55x forward PE (mild de-rating): Target Rs. 9,075-9,625
- Consensus analyst target (based on available data): Rs. 9,500-10,500 range
4. Sector Context:
The Indian private hospital sector consistently commands 50-80x PE because:
- Healthcare is a secular growth sector (India's healthcare spend rising from
<3.5% to 5%+ of GDP) - Bed shortage: India has ~1.4 beds per 1,000 population vs 3-4 for developed economies
- Pricing power: Hospital procedures have 8-12% annual price increases (inflation-proof)
- Limited competition for tertiary care (Apollo/Max/Fortis have built unassailable networks)
Valuation Verdict: EXPENSIVE (Absolute), FAIR (Sector-Relative)
At current PE (63.2x), Apollo is not cheap. But relative to peers and sector dynamics:
- Cheapest large-cap quality hospital stock (PE-adjusted for ROE)
- Apollo Healthtech demerger could unlock 10-15% additional value
- Stock near 52-week high — wait for 8-10% correction for better entry
Valuation Rating: 5/10 — Expensive in absolute terms, but sector-relative fair. Not a value pick; a quality pick.
Fundamental Score: 6.7/10
| Criteria | Score | Rationale |
|---|---|---|
| Business Quality | 9/10 | India's strongest healthcare brand; #1 hospital network; integrated pharmacy + digital moat; unassailable in tertiary care and medical tourism |
| Financial Health | 7/10 | Strong 15% revenue CAGR, accelerating profits (FY26: +33% YoY), first positive FCF (Rs. 925 Cr), strong interest coverage (9.6x). OPM constrained by pharmacy mix. |
| Shareholding Pattern | 5/10 | Low promoter holding (28.02%) is the main concern. Pledge (2.49%) acceptable. FII holding (42.62%) at world-class level signals quality. Risk of further equity dilution. |
| Valuation | 5/10 | PE 63.2x expensive in absolute terms. Cheapest large-cap quality hospital on PE/ROE and PB/ROE. Healthtech demerger adds upside option. Near-ATH limits near-term upside. |
| Growth Prospects | 7/10 | Structural healthcare growth in India; 2,000+ bed expansion pipeline; Apollo HealthCo building large digital health TAM; medical tourism recovery; pharmacy scale benefits |
| Risk Management | 7/10 | D/E 0.32x conservative; interest coverage 9.6x; cash conversion -89 days exceptional; diversified revenue across hospital, pharmacy, digital; limited single-customer dependency |
Composite Score: 6.7/10
Investment Thesis
Bull Case: Target Rs. 11,000-12,000 (+28-40% upside) — 30% probability
-
Apollo Healthtech Demerger Value Unlock: If the demerger creates a separately listed HealthCo entity (digital health + pharmacy tech), both companies could re-rate upward — hospital business would show 20-22% OPM (re-rating from 15%), while HealthCo could attract tech valuation multiples (5-10x revenue).
-
Bed Expansion Execution: Apollo targets 2,000+ new beds over 3 years. If Tier 2/3 city hospitals hit 65-70% occupancy within 3 years (Apollo's mature hospitals run at 70-75%), EBITDA could grow 30%+ annually in that segment, accelerating overall growth.
-
Medical Tourism Acceleration: India medical tourism market expected to reach USD 14 Bn by 2030. Apollo commands 20-25% market share. Any Middle East or Southeast Asia surge in outbound medical travel disproportionately benefits Apollo.
-
FY27 EPS Re-Rating: If net profit reaches Rs. 2,600+ Cr in FY27 (30% growth) and PE expands to 70x on re-rating momentum, target Rs. 12,000.
Bear Case: Target Rs. 6,500-7,000 (-20-25% downside) — 20% probability
-
Valuation De-Rating: If sector PE compresses from 60-75x to 40-50x (global risk-off, healthcare regulatory changes), stock could fall to Rs. 6,750-7,400 at 50x FY26 EPS.
-
Apollo HealthCo Losses Escalate: Apollo 24|7 digital health platform is pre-profit and cash-burning. If losses accelerate significantly (Rs. 1,000+ Cr/year) without clear profitability path, market may discount HealthCo negatively.
-
Promoter Dilution: Large equity raise for expansion (Rs. 3,000-5,000 Cr QIP) could dilute promoter below 25% and depress stock near-term.
-
Regulatory Risk: NHPS (Pradhan Mantri Jan Arogya Yojana) pricing caps on hospital procedures, or new SEBI/regulatory actions on healthcare pricing, could compress margins.
Base Case: Target Rs. 9,500-10,500 (+10-22% upside) — 50% probability
Assumptions:
- Revenue growth sustains 15-18% CAGR (FY26-FY28)
- Net profit grows 22-28% annually (operating leverage)
- FY27E EPS: Rs. 165-175; FY28E EPS: Rs. 205-220
- PE multiple maintained at 58-62x (slight compression from current 63x)
- Healthtech demerger proceeds without major disruption
- Bed expansion adds 800-1,000 new beds in FY27 (partial execution)
Outcome:
- FY27 Target: Rs. 9,575-10,850 (60x × Rs. 160-180 EPS)
- FY28 Target: Rs. 11,275-13,640 (55x × Rs. 205-248 EPS)
Expected Return Distribution:
- Bull Case (30% probability): +28-40% — Rs. 11,000-12,000
- Base Case (50% probability): +10-22% — Rs. 9,500-10,500
- Bear Case (20% probability): -20-25% — Rs. 6,500-7,000
Probability-Weighted Expected Return: ~+14% over 12 months
Technical Analysis
Technical Summary
Overall Signal: Bullish (Medium-Term), Cautious (Near-Term — Extended) Short-Term (1 month): Neutral-to-Bullish (near 52-week high, possible consolidation) Medium-Term (3-6 months): Bullish (strong uptrend intact)
Action: Accumulate on Dips (do NOT chase at current Rs. 8,591) Ideal Entry Zone: Rs. 7,800-8,200 (on correction to support) Stop Loss: Rs. 7,400 (below estimated 200-DMA support, close on weekly basis) Target 1: Rs. 9,500 (11% from current) Target 2: Rs. 10,500 (22% from current)
Price Action & Trend
Current Price: Rs. 8,591 (June 25, 2026)
| Moving Average | Estimated Value | Signal | Confidence |
|---|---|---|---|
| 50-Day SMA | ~Rs. 8,200-8,400 | Price above — Bullish | Estimate |
| 200-Day SMA | ~Rs. 7,600-7,900 | Price above — Bullish | Estimate |
| 20-Day EMA | ~Rs. 8,400-8,550 | Price above — Short-term bullish | Estimate |
Note: Exact MA values not available from web sources. Estimates based on 1-year stock CAGR of 22% and 52-week range.
52-Week Range: Rs. 6,680 (Low) — Rs. 8,690 (High)
Position in 52-Week Range: ~95% — Near 52-week high
Trend Assessment:
- Strong 1-year uptrend: from Rs. 7,041 (est. one year ago) to Rs. 8,591 today (+22%)
- Stock has consistently made higher highs and higher lows over 3-5 year period
- Near 52-week high (Rs. 8,690) is a minor resistance; breakout above would signal strength
- Stock is technically extended from likely 200-DMA (estimated Rs. 7,600-7,900) — suggests pullback risk before next leg up
Momentum Indicators
| Indicator | Estimated Value | Signal | Interpretation |
|---|---|---|---|
| RSI (14-day) | ~65-72 (est.) | Moderately Overbought | Near ATH; approaching caution zone |
| MACD | Likely Positive | Bullish | Uptrend confirmation |
| MACD Signal | Positive | Bullish trend | |
| Stochastic | ~75-85 (est.) | Overbought | Price at high of recent range |
Note: RSI and MACD are estimated based on price position. Exact values require real-time charting tool.
RSI Analysis: Estimated RSI of 65-72 suggests the stock has strong momentum but is approaching overbought levels. At near-ATH prices, any negative catalyst could trigger RSI reversal. A healthy pullback to 50-55 RSI (corresponding to ~Rs. 7,800-8,200 price) would create better risk-reward entry.
MACD Analysis: With stock in strong uptrend and near 52-week high, MACD is likely positive and above signal line. Bullish momentum intact.
Volume Analysis
| Metric | Value | Assessment |
|---|---|---|
| Recent Volume | ~2.92 L shares/day | Standard |
| Position | Near 52-week high | Accumulation signal if high volume |
| Interpretation | Moderate volume at highs | Decent but not explosive breakout volume |
Volume Assessment: Volume at near-ATH levels should ideally be 2-3x average for confirmed breakout. Moderate volume suggests institutional holding rather than speculative retail chasing. Not alarming but not a strong breakout signal either.
Support & Resistance Levels
| Level | Price (Rs.) | Significance |
|---|---|---|
| Major Resistance / ATH | 8,690 | 52-week high — potential breakout target |
| Immediate Resistance | 8,600-8,690 | Current zone — minor resistance band |
| Current Price | 8,591 | Current as of June 25, 2026 |
| Short-Term Support | 8,200-8,400 | Estimated 50-DMA zone |
| Key Support | 7,800-8,000 | Prior breakout level / accumulation zone |
| Strong Support | 7,600-7,900 | Estimated 200-DMA zone |
| Major Support | 6,680 | 52-week low |
Chart Pattern
Pattern: Extended Uptrend near ATH — potential for Breakout or Consolidation
Pattern Assessment:
- Stock is 95% up its 52-week range — near prior highs
- Two scenarios from here:
- Scenario A (Breakout): Sustained move above Rs. 8,690 on strong volume → target Rs. 9,500-10,000. Probability: 40%
- Scenario B (Consolidation/Pullback): Stock consolidates in Rs. 7,800-8,690 range for 4-8 weeks → better entry at Rs. 7,800-8,200. Probability: 60%
VCP Check: Not clearly forming a VCP at current levels. Better VCP setup would require stock to pull back to Rs. 8,000-8,200 range with declining volume contraction before next breakout.
Entry & Exit Strategy
Entry Strategy:
- Preferred Entry: Rs. 7,800-8,200 (on pullback — 5-8% from current)
- Aggressive Entry: Rs. 8,400-8,600 (immediate, accept limited near-term upside)
- Breakout Entry: Rs. 8,700+ with volume confirmation (momentum play)
Position Sizing: 3-5% of portfolio (large-cap quality stock, lower risk than small/mid-cap)
Risk per trade: Keep stop loss to <2% of portfolio (stop at Rs. 7,400)
Exit Strategy:
- Target 1 (partial — 50%): Rs. 9,500 — sell half position
- Target 2 (full): Rs. 10,500 — sell remaining
- Stop Loss: Rs. 7,400 (below 200-DMA support) — exit fully on weekly close below
- Trailing Stop: Move stop to entry cost once Target 1 reached
Technical Risk Assessment
Technical Risk Level: MEDIUM (near ATH but strong uptrend intact)
- Stock is ~95% of 52-week range — limited near-term upside until breakout confirmed
- Estimated RSI 65-72 suggests mild overextension — pullback to Rs. 7,800-8,200 is healthy and likely before next leg
- Long-term uptrend (20% CAGR stock for 5 years) is intact; there's no technical breakdown signal
- Key risk: If Healthtech demerger faces NCLT delays or market-wide sell-off, could trigger 10-15% correction
Fundamental vs Technical Alignment
| Dimension | Signal | Notes |
|---|---|---|
| Fundamental | Bullish (Medium-High) | Score 6.7/10 — quality business at fair sector valuation |
| Technical | Bullish (but extended) | Near ATH, uptrend intact, pullback risk before continuation |
| Alignment | Aligned | Both suggest medium-term upside; both suggest patience near-term |
| Recommendation | Buy on Dips | Wait for Rs. 7,800-8,200 entry for best risk-reward |
Combined Conviction: Medium-High
Fundamental and technical signals are aligned — quality company in uptrend with both suggesting better risk-reward on a pullback. Current levels (Rs. 8,591) offer limited near-term upside given proximity to ATH. Patient investors who wait for Rs. 7,800-8,200 entry get better margin of safety with the same long-term thesis.
Risk Assessment
| Risk | Probability | Impact | Details |
|---|---|---|---|
| Valuation De-Rating | Medium | High | Sector PE could compress from 65-75x to 45-55x in global risk-off. Healthcare is defensive but not immune to multiple compression. |
| Apollo HealthCo Losses | Medium | Medium | Digital health pre-profit segment burning cash. If HealthCo losses exceed Rs. 500-800 Cr annually, consolidated profits dampened. Demerger reduces this risk. |
| Promoter Dilution | Medium | Medium | Company will need Rs. 3,000-5,000 Cr equity over 3 years for expansion. Each large QIP dilutes promoter stake further (currently 28.02%). |
| Regulatory / NHA Pricing | Low-Medium | High | Government health schemes (PM-JAY) cap procedure rates. If hospitals are mandated to treat a minimum % at capped rates, margins compress. |
| Competition from Digital | Low | Medium | Reliance (Netmeds + JioHealth), Tata (1mg), Practo — competing for pharmacy and digital health share. Apollo 24x7 must scale fast to win. |
| Demerger Execution Risk | Low | Medium | Apollo Healthtech demerger requires NCLT approval + shareholder vote. Complexity could delay timeline, creating uncertainty overhang. |
| Key Person Risk | Low | Medium | Dr. Prathap C. Reddy is 82 years old. Succession is to Suneeta Reddy (MD) and Sangita Reddy (JMD) — family succession plan in place, reducing risk. |
| Medical Tourism Disruption | Low | Low | Any major geopolitical event or pandemic could reduce international patient volumes (10-15% of hospital revenue). Short-term risk only. |
Overall Risk Rating: MEDIUM (5/10) — Manageable for a quality large-cap. Main risks are valuation-driven (sector PE de-rating) and strategic (HealthCo execution), not fundamental business deterioration.
Catalysts
Near-Term (0-3 Months):
-
Apollo Healthtech Demerger Outcome (July-August 2026): NCLT meeting held June 24, 2026. Approval + demerger completion could trigger 10-20% re-rating as the hospital business premium valuation is unlocked separately from HealthCo.
-
Q1 FY27 Earnings (July-August 2026): Track Q1 FY27 revenue and OPM. If revenue exceeds Rs. 7,000 Cr and OPM improves to 16%+, strong positive catalyst. Q4 FY26 annualized run rate implies Rs. 6,900+ Cr for Q1 FY27 is achievable.
-
Apollo Pharmacy Q1 Update: Monthly sales data from Apollo Pharmacy — if store count exceeds 6,500 and same-store growth maintains 8-10%, confirms pharmacy flywheel.
Medium-Term (3-12 Months):
-
New Bed Commissioning: Announcement of 500-800 new beds added across new hospitals in FY27. Capacity expansion is the primary growth engine for hospital EBITDA.
-
Apollo 24|7 Active Users Milestone: If Apollo 24|7 crosses 10 million monthly active users, demonstrates digital health scale — potential for HealthCo to attract growth valuation post-demerger.
-
Analyst Coverage Upgrade: Multiple large brokerages (currently valuing at Rs. 9,000-10,500) could raise targets significantly if Q1 FY27 beats expectations — institutional buying surge.
-
MSCI Weight Increase: Apollo's increasing market cap and free float could lead to higher MSCI weight, triggering passive fund buying.
Long-Term (1-3 Years):
-
Hospital EBITDA Margin Expansion to 22-25%: As new hospitals ramp up occupancy and pharmacy grows scale, consolidated OPM could expand from 15% to 18-20% by FY28-FY29, significantly re-rating the stock.
-
Apollo HealthCo Profitability: If Apollo 24|7 / HealthCo reaches profitability by FY28, the currently cash-burning segment becomes a profit contributor — significant EPS uplift.
-
Medical Tourism India Hub Status: India's USD 14 Bn medical tourism target by 2030. Apollo is the primary beneficiary — a dedicated international patient facility (akin to an international hospital) could be a major growth initiative.
-
International Expansion: Apollo's brand recognition in Southeast Asia and Middle East could support limited international hospital expansion (management contracts, JVs) — opens new revenue stream without heavy capex.
Key Monitoring Parameters
Quarterly (every earnings release):
- Revenue Growth: Target
>15% YoY. Below 12% for two consecutive quarters = concern. - OPM Trend: Target 15-17% consolidated. Improvement toward 16%+ signals pharmacy scale benefits.
- Net Profit Growth: Target
>20% YoY. Accelerating EPS growth is the key re-rating trigger. - OCF vs Capex: Ensure operating cash flow (
>Rs. 700 Cr/quarter) covers capex. Negative FCF for>2 years would be concerning. - Bed Count: New beds commissioned quarterly. Target 500+ beds/year.
- Promoter Holding: Watch for dilution below 25% — would raise governance concerns.
Annual Metrics:
- ARPOB (Average Revenue Per Occupied Bed): Should increase 8-12% annually — pricing power indicator.
- Occupancy Rate: Target 68-72% for mature hospitals. New hospitals typically ramp to 50% in year 2, 65%+ by year 3.
- Apollo HealthCo losses: Should narrow — if losses exceed Rs. 800 Cr annually, strategic review needed.
- Demerger Progress: Status of NCLT approval for Healthtech demerger.
Trigger Events:
✅ Buy More:
- Healthtech demerger approved + hospital segment PE re-rates to 65-70x
- Two consecutive quarters of 17%+ consolidated OPM
- Stock pulls back to Rs. 7,800-8,200 without fundamental change
- Major new hospital announcement (100+ beds capacity, tier 1 city)
🔻 Reduce / Exit:
- Net profit growth falls below 10% YoY for two consecutive quarters
- Promoter holding falls below 25% via large equity placement
- NHPS/regulatory caps significantly reduce procedure pricing
- Apollo HealthCo losses accelerate beyond Rs. 1,000 Cr/year
- Stock falls below Rs. 7,400 on closing weekly basis (200-DMA breakdown)
Conclusion
Apollo Hospitals is India's premier integrated healthcare franchise — the gold standard of private hospital care with an unassailable 40-year brand moat, India's largest hospital network, the largest pharmacy chain, and an emerging digital health platform. The company has crossed a pivotal inflection point in FY26: first positive FCF (Rs. 925 Cr), accelerating net profit growth (33% YoY to Rs. 2,003 Cr), and quarterly revenues consistently above Rs. 6,000 Cr.
The valuation (PE 63.2x) looks expensive in absolute terms but is the most quality-adjusted cheap stock among large-cap Indian hospitals (cheapest PE/ROE among Max, Fortis, Apollo). The impending Apollo Healthtech demerger (NCLT meeting June 24, 2026) is the single most important near-term event — approval and implementation could add 10-20% to valuations by separating the hospital business (high-OPM, PE-worthy) from the digital health entity.
Technical picture supports the bullish fundamental view — stock is in a confirmed 5-year uptrend with 20% annual CAGR returns. However, at 95% of its 52-week range (Rs. 8,591 vs ATH Rs. 8,690), entry at current levels offers limited near-term upside. The ideal setup is a 5-8% pullback to Rs. 7,800-8,200 range, which would be consistent with the stock consolidating before its next leg toward Rs. 10,000+.
Investment Recommendation: Buy on Dips (Rs. 7,800-8,200 target entry) Suitable For: Long-term investors (3+ years), healthcare sector allocators, quality-growth investors seeking Nifty 50 exposure with fundamental depth Portfolio Allocation: 3-5% of total portfolio (low-medium risk large-cap) Time Horizon: 18-24 months for Rs. 10,000-10,500 base case target
Investment Suitability
Ideal Investor Profile:
- Long-term investor (3+ years) comfortable with quality-growth premium valuations
- Healthcare sector allocation in diversified portfolio
- Investors wanting exposure to India's structural healthcare growth story
- Comfortable holding through 10-15% market volatility
Not Suitable For:
- Deep value investors seeking PE below 30x
- Dividend income investors (yield only 0.22%)
- Investors with
<1 year horizon (near-ATH limits near-term upside) - Investors uncomfortable with 20-25% potential drawdown in global risk-off
Peer Comparison Summary
| Metric | Apollo Hospitals | Max Healthcare | Fortis | Narayana H | Best |
|---|---|---|---|---|---|
| Revenue (Rs. Cr FY26) | 25,228 | 8,373 | 9,128 | 7,896 | Apollo |
| Net Profit (Rs. Cr) | 2,003 | 1,442 | 1,064 | 806 | Apollo |
| ROE | 22.1% | 14.8% | 11.3% | 20.9% | Apollo |
| ROCE | 17.9% | 14.7% | 13.5% | 15.4% | Apollo |
| D/E Ratio | 0.32x | 0.36x | 0.35x | 1.29x | Apollo |
| PE Ratio | 63.2x | 74.2x | 68.9x | 46.8x | NH |
| PE/ROE | 2.86 | 5.01 | 6.09 | 2.24 | NH |
| PB/ROE | 0.593 | 0.696 | 0.664 | 0.426 | NH |
| OPM | 15%* | 27% | 23% | 20% | Max* |
| Scale/Brand Moat | #1 | #2 | #3 | #4 | Apollo |
*Apollo OPM includes pharmacy; hospital-only OPM ~20-22%
Verdict: Apollo Hospitals leads on absolute financials (revenue, profit, ROE, ROCE), has the strongest moat, and is actually cheaper than Max Healthcare and Fortis on quality-adjusted metrics. Only Narayana Hrudayalaya offers cheaper entry but with significantly higher debt (1.29x D/E).
For pure hospital exposure with lower valuation: Narayana Hrudayalaya (46.8x PE, 20.9% ROE, but D/E 1.29x) For integrated healthcare platform with strongest moat: Apollo Hospitals (recommended)
Related Analyses
Existing Related Analyses:
- US Market Bubble Evaluation 2026 - Macro market context
Potential Future Analyses to Enhance This Report:
- Max Healthcare - Comprehensive Analysis - Direct hospital peer for comparison
- Narayana Hrudayalaya - Fundamental Analysis - Cheaper entry alternative
- Fortis Healthcare - Fundamental Analysis - Third large-cap peer
- Healthcare Sector Overview - Sector-level trends, bed shortage data, NHPS impact, medical tourism
Disclaimer
This analysis is for educational and informational purposes only and does not constitute investment advice. Stock markets are subject to risks, and past performance is not indicative of future results. The information presented is based on publicly available data as of June 25, 2026, and may become outdated as new information emerges.
Specific Notes for Apollo Hospitals:
- Technical indicators (moving averages, RSI, MACD) are estimated based on price position and CAGR; exact values require live charting tools
- Apollo Healthtech demerger approval is pending NCLT + shareholder approval; outcome uncertain
- Consolidated OPM includes pharmacy operations (3-5% OPM); hospital segment OPM estimated at ~20-22% — adjust peer comparisons accordingly
- Promoter pledge (2.49%) was sourced from finology.in; verify via NSE shareholding pattern filings
Investors should conduct their own due diligence, consult a qualified financial advisor, and consider their own risk tolerance before making investment decisions.
Data Sources
- Screener.in — Consolidated financials, ratios, shareholding, cash flows (Accessed: June 25, 2026)
- Screener.in (Peers) — Max Healthcare, Fortis, Narayana Hrudayalaya data (Accessed: June 25, 2026)
- Finology.in — Promoter pledge, EV/EBITDA, technical overview (Accessed: June 25, 2026)
Data Timestamp: June 25, 2026, ~12:58 PM IST (Stock Price: Rs. 8,591, Market Cap: Rs. 1,23,520 Cr)
Next Update Recommended: After Q1 FY27 earnings (July-August 2026) OR Apollo Healthtech demerger NCLT approval announcement.
Report Generated: June 25, 2026 | Version: 1.0 | Analyst: Claude (AI-powered financial analysis)